Gastroenteropancreatic Neuroendocrine Neoplasms: Incidence, Treatment, and Outcomes
Author Information
Author(s): Uhlig Johannes, Nie James, Gibson Joanna, Cecchini Michael, Stein Stacey, Lacy Jill, Kunz Pamela, Kim Hyun S.
Primary Institution: Yale School of Medicine
Hypothesis
To investigate incidence, treatment patterns and outcomes of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) in the United States.
Conclusion
The number of GEP-NEN cases has increased significantly, likely due to improved detection and diagnosis, and treatment patterns have evolved to follow the latest international guidelines.
Supporting Evidence
- Overall survival was evaluated using averaged Cox regression.
- Most patients received surgery, either alone (72.9%) or in combination with systemic therapy (4.9%).
- Having higher income and private insurance or Medicare was associated with improved survival.
- GEP-NEN incidence increases, likely due to improved detection and diagnosis.
- Treatment patterns have evolved to follow the latest international guidelines.
Takeaway
This study looked at a lot of patients with a specific type of cancer and found that more people are being diagnosed, and treatments are getting better.
Methodology
The study analyzed data from the 2019 National Cancer Database for adult GEP-NEN patients diagnosed between 2004 and 2016.
Potential Biases
The study may not fully capture the heterogeneity of histological subtypes and relies on hospital-based data.
Limitations
The NCDB data are not representative of the general US population and do not report specific tumor variables like Ki-67 or mitotic rate.
Participant Demographics
Patients had a median age of 58 years, with 48.7% male and 51.3% female.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 2.81–3.52
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website